What is SABS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.27B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SABS?

P/E (TTM) is 20.43 and 52-week range is $2.10 to $5.15 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SABS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SABS?

The company profile lists revenue (TTM) near $1M, net income (TTM) near $-2.38B, EPS (TTM) near $-1.42 when available from the market-data feed. Figures are informational and may lag live markets.

Where is SAB Biotherapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Miami Beach, Florida, US, 76.5M shares outstanding, ISIN US78397T2024 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

SAB Biotherapeutics Inc

$SABS

Health Care · Biotechnology

IR Run Scenarios

$2.98

+3.11%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company, which engages in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The company is headquartered in Miami Beach, Florida and currently employs 86 full-time employees. The company went IPO on 2021-01-12. The firm is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.

Employees

Website

www.sab.bio/

IPO

2021-01-12

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)